Table 1 Patient characteristics
[18F]FCH (n = 23) | [18F]DCFPyL (n = 19) | P value | |
|---|---|---|---|
Age (y) | 61.1 ± 6.9 (49–76)* | 62.4 ± 4.7 (50–67)* | 0.58 |
Weight (kg) | 93.3 ± 14.3 (67–122)* | 86.4 ± 17.1 (30–109)* | 0.46 |
Height (cm) | 175.7 ± 5.0 (168–185)* | 177.1 ± 6.3 (165–191)* | 0.37 |
PSA (ng/mL) | 5.9 ± 3.4 (0.9–15.0)* | 8.4 ± 5.8 (3.5–25.5)* | 0.42 |
Histology—n(%) | 1.00 | ||
Adenocarcinoma | 23 (100) | 19 (100) | |
pT stage—n(%) | 0.93 | ||
T2a | 1 (4.3) | 0 (0) | |
T2c | 12 (52.2) | 11 (57.9) | |
T3a | 5 (21.7) | 7 (36.8) | |
T3b | 5 (21.7) | 1 (5.3) | |
pN stage—n(%) | 0.79 | ||
N0 | 19 (82.6) | 19 (100) | |
N1 | 1 (4.3) | 0 (0) | |
NX | 3 (13.0) | 0 (0) | |
Gleason score—n(%) | 0.94 | ||
6 (3 + 3) | 2 (8.7) | 1 (5.3) | |
7 (3 + 4) | 17 (69.6) | 16 (84.2) | |
7 (4 + 3) | 4 (17.4) | 2 (10.5) | |
9 (5 + 4) | 1 (4.3) | 0 (0) | |
Proportion of prostate involved by tumour (%) | 14.3 ± 15.5 (1–80)* | 13.7 ± 7.7 (5–30)* | 0.49 |